There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight-loss drug in 2021.

The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study finds.

A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

As a result, estimated annual spending on GLP-1 drugs among non-diabetics rose from $1.6 billion between 2018 and 2021 to $5.8 billion in 2022, the study showed.

As a result, estimated annual spending on GLP-1 drugs among non-diabetics rose from $1.6 billion between 2018 and 2021 to $5.8 billion in 2022, the study showed.

The study found a sharp increase in the share of patients who received GLP-1 RAs during the study period, with GLP-1 RA use increasing 132.6% from the last six months of 2022 to the last six ...

"Our findings also show that while the benefits of GLP-1 drugs are significant, their use does come with some added risk of diabetic retinopathy, suggesting that physicians need to carefully ...

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

For the study, researchers analyzed the medical data of about 45 million Americans between 2011 and 2023. About 1 million people became new GLP-1 users during that period in time, results show.

At the same time, the proportion of people using the drugs to control type 2 diabetes has declined Semaglutide is being used disproportionately by females, whites and people with obesity TUESDAY ...

Study shows shift in GLP-1 drug use for obesity, not diabetes. Dennis Thompson, HealthDay News. Tue, July 23, 2024 at 5:58 PM UTC. 2 min read.